Safety and Cognitive Function Study of EVP-6124 in Patients With Schizophrenia
Status:
Completed
Trial end date:
2011-03-01
Target enrollment:
Participant gender:
Summary
This study is being conducted to determine the safety and effect on cognitive function of two
different doses of an investigational medication, EVP-6124, in individuals with schizophrenia
who are on chronic stable atypical anti-psychotic therapy. In addition, behavioral and
psychotic symptoms will be evaluated.